Effectiveness of BNT162b2 Against Infection, Symptomatic Infection, and Hospitalization Among Older Adults Aged ≥65 Years During the Delta Variant Predominance in Japan: The VENUS Study

DOI Web Site PubMed 21 References Open Access
  • Mimura Wataru
    Section of Clinical Epidemiology, Department of Data Science, Center for Clinical Sciences, National Center for Global Health and Medicine
  • Ishiguro Chieko
    Section of Clinical Epidemiology, Department of Data Science, Center for Clinical Sciences, National Center for Global Health and Medicine
  • Terada-Hirashima Junko
    Department of Respiratory Medicine, Center Hospital of the National Center for Global Health and Medicine
  • Matsunaga Nobuaki
    AMR Clinical Reference Center, National Center for Global Health and Medicine
  • Sato Shuntaro
    Clinical Research Center, Nagasaki University Hospital
  • Kawazoe Yurika
    Clinical Research Center, Nagasaki University Hospital
  • Maeda Megumi
    Department of Health Care Administration and Management, Kyushu University Graduate School of Medical Sciences
  • Murata Fumiko
    Department of Health Care Administration and Management, Kyushu University Graduate School of Medical Sciences
  • Fukuda Haruhisa
    Department of Health Care Administration and Management, Kyushu University Graduate School of Medical Sciences

Description

<p>Background: We evaluated the effectiveness of the BNT162b2 vaccine against infection, symptomatic infection, and hospitalization in older people during the Delta-predominant period (July 1 to September 30, 2021).</p><p>Methods: We performed a population-based cohort study in an older adult population aged ≥65 years using data from the Vaccine Effectiveness, Networking, and Universal Safety Study conducted from January 1, 2019, to September 30, 2021, in Japan. We matched BNT162b2-vaccinated and -unvaccinated individuals in a 1:1 ratio on the date of vaccination of the vaccinated individual. We evaluated the effectiveness of the vaccine against infection, symptomatic infection, and coronavirus disease (COVID-19)-related hospitalization by comparing the vaccinated and unvaccinated groups. We estimated the risk ratio and risk difference using the Kaplan–Meier method with inverse probability weighting. The vaccine effectiveness was calculated as (1 − risk ratio) × 100%.</p><p>Results: The study included 203,574 matched pairs aged ≥65 years. At 7 days after the second dose, the vaccine effectiveness of BNT162b2 against infection, symptomatic infection, and hospitalization was 78.1% (95% confidence interval [CI], 65.2–87.8%), 79.1% (95% CI, 64.6–88.9%), and 93.5% (95% CI, 83.7–100%), respectively.</p><p>Conclusion: BNT162b2 was highly effective against infection, symptomatic infection, and hospitalization in Japan’s older adult population aged ≥65 years during the Delta-predominant period.</p>

Journal

References(21)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top